BioEclipse Therapeutics
Oliver Hopkinson joined BioEclipse’s Board of Directors in 2019 as a representative of Revelis Capital Group, a Colorado-based venture firm that invests across a range of disruptive, early-stage tech companies. Mr. Hopkinson co-founded Revelis in early 2017, and currently serves as its Managing Principal, overseeing all aspects of its investment operations. To date, Revelis has consummated Series Seed and Series A investments in the biotech, software and data/blockchain sectors. Mr. Hopkinson graduated with a B.S. in Economics from Duke University in 2016, and he is a J.D. candidate at University of Colorado Law School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
BioEclipse Therapeutics
BioEclipse Therapeutics is a clinical-stage oncology company that develops immuno-oncology therapeutics using its proprietary technology.